PL4199922T3 - Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych - Google Patents
Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowychInfo
- Publication number
- PL4199922T3 PL4199922T3 PL21765908.5T PL21765908T PL4199922T3 PL 4199922 T3 PL4199922 T3 PL 4199922T3 PL 21765908 T PL21765908 T PL 21765908T PL 4199922 T3 PL4199922 T3 PL 4199922T3
- Authority
- PL
- Poland
- Prior art keywords
- phenylthiazol
- cyclopentane
- carbamoyl
- cyano
- treatment
- Prior art date
Links
- MSZKZEFOAPULKG-NWDGAFQWSA-N (1r,3s)-3-[(5-cyano-4-phenyl-1,3-thiazol-2-yl)carbamoyl]cyclopentane-1-carboxylic acid Chemical compound C1[C@H](C(=O)O)CC[C@@H]1C(=O)NC1=NC(C=2C=CC=CC=2)=C(C#N)S1 MSZKZEFOAPULKG-NWDGAFQWSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382764.7A EP3957308A1 (en) | 2020-08-21 | 2020-08-21 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| PCT/EP2021/073133 WO2022038261A1 (en) | 2020-08-21 | 2021-08-20 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4199922T3 true PL4199922T3 (pl) | 2025-02-10 |
Family
ID=72234795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21765908.5T PL4199922T3 (pl) | 2020-08-21 | 2021-08-20 | Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230321053A1 (https=) |
| EP (2) | EP3957308A1 (https=) |
| JP (1) | JP7794807B2 (https=) |
| KR (1) | KR20230054444A (https=) |
| CN (1) | CN115942933A (https=) |
| AU (1) | AU2021327728A1 (https=) |
| BR (1) | BR112023002778A2 (https=) |
| CA (1) | CA3190081A1 (https=) |
| DK (1) | DK4199922T3 (https=) |
| ES (1) | ES3001104T3 (https=) |
| FI (1) | FI4199922T3 (https=) |
| HR (1) | HRP20241621T1 (https=) |
| HU (1) | HUE069338T2 (https=) |
| LT (1) | LT4199922T (https=) |
| MX (1) | MX2023002156A (https=) |
| PL (1) | PL4199922T3 (https=) |
| PT (1) | PT4199922T (https=) |
| RS (1) | RS66263B1 (https=) |
| SI (1) | SI4199922T1 (https=) |
| WO (1) | WO2022038261A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| KR20160061352A (ko) | 2013-10-15 | 2016-05-31 | 메디뮨 엘엘씨 | 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 |
| UA122670C2 (uk) * | 2014-09-08 | 2020-12-28 | Сефалон, Інк. | Спосіб лікування еозинофільної астми у пацієнта |
| ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
-
2020
- 2020-08-21 EP EP20382764.7A patent/EP3957308A1/en not_active Withdrawn
-
2021
- 2021-08-20 RS RS20241285A patent/RS66263B1/sr unknown
- 2021-08-20 CA CA3190081A patent/CA3190081A1/en active Pending
- 2021-08-20 MX MX2023002156A patent/MX2023002156A/es unknown
- 2021-08-20 PL PL21765908.5T patent/PL4199922T3/pl unknown
- 2021-08-20 HU HUE21765908A patent/HUE069338T2/hu unknown
- 2021-08-20 FI FIEP21765908.5T patent/FI4199922T3/fi active
- 2021-08-20 DK DK21765908.5T patent/DK4199922T3/da active
- 2021-08-20 AU AU2021327728A patent/AU2021327728A1/en active Pending
- 2021-08-20 KR KR1020237009717A patent/KR20230054444A/ko active Pending
- 2021-08-20 CN CN202180051106.2A patent/CN115942933A/zh active Pending
- 2021-08-20 HR HRP20241621TT patent/HRP20241621T1/hr unknown
- 2021-08-20 LT LTEPPCT/EP2021/073133T patent/LT4199922T/lt unknown
- 2021-08-20 US US18/040,508 patent/US20230321053A1/en active Pending
- 2021-08-20 WO PCT/EP2021/073133 patent/WO2022038261A1/en not_active Ceased
- 2021-08-20 BR BR112023002778A patent/BR112023002778A2/pt unknown
- 2021-08-20 PT PT217659085T patent/PT4199922T/pt unknown
- 2021-08-20 EP EP21765908.5A patent/EP4199922B1/en active Active
- 2021-08-20 ES ES21765908T patent/ES3001104T3/es active Active
- 2021-08-20 JP JP2023512647A patent/JP7794807B2/ja active Active
- 2021-08-20 SI SI202130242T patent/SI4199922T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230321053A1 (en) | 2023-10-12 |
| EP3957308A1 (en) | 2022-02-23 |
| RS66263B1 (sr) | 2024-12-31 |
| JP2023538419A (ja) | 2023-09-07 |
| EP4199922B1 (en) | 2024-09-25 |
| DK4199922T3 (da) | 2024-11-25 |
| SI4199922T1 (sl) | 2025-03-31 |
| HRP20241621T1 (hr) | 2025-01-31 |
| KR20230054444A (ko) | 2023-04-24 |
| PT4199922T (pt) | 2024-12-18 |
| BR112023002778A2 (pt) | 2023-03-14 |
| LT4199922T (lt) | 2025-01-10 |
| AU2021327728A1 (en) | 2023-03-09 |
| JP7794807B2 (ja) | 2026-01-06 |
| CA3190081A1 (en) | 2022-02-24 |
| FI4199922T3 (fi) | 2024-12-05 |
| HUE069338T2 (hu) | 2025-02-28 |
| WO2022038261A1 (en) | 2022-02-24 |
| EP4199922A1 (en) | 2023-06-28 |
| MX2023002156A (es) | 2023-03-01 |
| ES3001104T3 (es) | 2025-03-04 |
| CN115942933A (zh) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| MX2024010140A (es) | Nuevos metodos. | |
| IL273169A (en) | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| SA520411119B1 (ar) | تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها | |
| WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| IL285238A (en) | Gene therapy vectors for treatment of danon disease | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| WO2017062468A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| MX2022003128A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| PL4199922T3 (pl) | Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych | |
| HUE060322T2 (hu) | Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra | |
| WO2018115432A3 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE | |
| IL277599A (en) | Use of (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| EP4566629A3 (en) | Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages | |
| CL2021000160A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| PL3813816T3 (pl) | Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x | |
| EP4426686A4 (en) | N,N-DIMETHYLAMPHTAMIN ANALOGUES FOR THE TREATMENT OF CEREBRAL DISORDERS | |
| EP4221704A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES | |
| LT4182311T (lt) | 1-metil-1h-pirazol-3-ilo dariniai, skirti naudoti neovaskulinių ligų gydymui | |
| WO2016049580A3 (en) | Inhibitors of nf kappa-b activity for treatment of diseases and disorders | |
| HUP2300429A1 (hu) | Aminoalkilezett benzoxivegyületek szívrendellenességek kezelésében történõ alkalmazásra |